204 related articles for article (PubMed ID: 38224427)
21. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Cejuela M; Gil-Torralvo A; Castilla MÁ; Domínguez-Cejudo MÁ; Falcón A; Benavent M; Molina-Pinelo S; Ruiz-Borrego M; Salvador Bofill J
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239834
[TBL] [Abstract][Full Text] [Related]
22. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
24. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK
Breast Cancer Res Treat; 2019 Feb; 174(1):271-278. PubMed ID: 30465154
[TBL] [Abstract][Full Text] [Related]
25. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy.
Marineau A; St-Pierre C; Lessard-Hurtubise R; David MÈ; Adam JP; Chabot I
J Oncol Pharm Pract; 2023 Jul; 29(5):1144-1153. PubMed ID: 35642282
[TBL] [Abstract][Full Text] [Related]
27. Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor.
Chan OB; Su JC; Yazdabadi A; Chan A
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e154-e156. PubMed ID: 34180575
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
29. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
30. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
31. Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation.
Anjaneyan G; Keechilat P; Duraisamy P; Eapen M
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35365472
[TBL] [Abstract][Full Text] [Related]
32. Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan.
Sawaki M; Muramatsu Y; Togo K; Iwata H
Breast; 2023 Aug; 70():1-7. PubMed ID: 37267715
[TBL] [Abstract][Full Text] [Related]
33. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
34. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
35. Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
Kawamoto T; Shikama N; Imano N; Kubota H; Kosugi T; Sekii S; Harada H; Yamada K; Naoi Y; Miyazawa K; Hirano Y; Wada Y; Tonari A; Saito T; Uchida N; Araki N; Nakamura N
Breast Cancer; 2023 Mar; 30(2):282-292. PubMed ID: 36528759
[TBL] [Abstract][Full Text] [Related]
36. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
37. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Figura NB; Potluri TK; Mohammadi H; Oliver DE; Arrington JA; Robinson TJ; Etame AB; Tran ND; Liu JK; Soliman H; Forsyth PA; Sahebjam S; Yu HM; Han HS; Ahmed KA
J Neurooncol; 2019 Sep; 144(3):583-589. PubMed ID: 31399935
[TBL] [Abstract][Full Text] [Related]
38. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini C; Visani L; Caini S; Bhattacharya IS; Kirby AM; Nader Marta G; Morgan G; Salvestrini V; Coles CE; Cortes J; Curigliano G; de Azambuja E; Harbeck N; Isacke CM; Kaidar-Person O; Marangoni E; Offersen B; Rugo HS; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
Cancer Treat Rev; 2023 Sep; 119():102586. PubMed ID: 37336117
[TBL] [Abstract][Full Text] [Related]
39. The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
Nakatsukasa H; Takahashi M; Takahashi K; Takashima T; Asano Y; Morisaki T; Kashiwagi S; Noda S; Nakamura Y
Biol Pharm Bull; 2022; 45(10):1476-1481. PubMed ID: 36184505
[TBL] [Abstract][Full Text] [Related]
40. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice.
Sibaud V; Sollena P
Ann Dermatol Venereol; 2023 Sep; 150(3):208-212. PubMed ID: 37586898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
